Analysis of the Putative Role of CR1 in Alzheimer’s Disease: Genetic Association, Expression and Function
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Chronic activation of the complement system and induced inflammation are associated with neuropathology in Alzheimer's disease (AD). Recent large genome wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) in the C3b/C4b receptor (CR1 or CD35) that are associated with late onset AD. Here, anti-CR1 antibodies (Abs) directed against different epitopes of the receptor, were used to localize CR1 in brain, and relative binding affinities of the CR1 ligands, C1q and C3b, were assessed by ELISA. Most Abs tested stained red blood cells in blood vessels but showed no staining in brain parenchyma. However, two monoclonal anti-CR1 Abs labeled astrocytes in all of the cases tested, and this reactivity was preabsorbed by purified recombinant human CR1. Human brain-derived astrocyte cultures were also reactive with both mAbs. The amount of astrocyte staining varied among the samples, but no consistent difference was conferred by diagnosis or the GWAS-identified SNPs rs4844609 or rs6656401. Plasma levels of soluble CR1 did not correlate with diagnosis but a slight increase was observed with rs4844609 and rs6656401 SNP. There was also a modest but statistically significant increase in relative binding activity of C1q to CR1 with the rs4844609 SNP compared to CR1 without the SNP, and of C3b to CR1 in the CR1 genotypes containing the rs6656401 SNP (also associated with the larger isoform of CR1) regardless of clinical diagnosis. These results suggest that it is unlikely that astrocyte CR1 expression levels or C1q or C3b binding activity are the cause of the GWAS identified association of CR1 variants with AD. Further careful functional studies are needed to determine if the variant-dictated number of CR1 expressed on red blood cells contributes to the role of this receptor in the progression of AD, or if another mechanism is involved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 Representation of CR1 structure, ligand binding sites and location of antibody epitopes. CYT: cytoplasmic domain, TM: transmembrane domain. Red dot indicates location of rs4844609 (Ser1610Thr). Diagram modified from[16]; Antibody reactivity modified from[17].](https://figures.cochat.ai/paper-figures/14cc88966a5949c2bc8a0c8df41edee9/analysis-of-the-putative-role-of-cr1-in-alzheimers-disease-genetic-association-figure-1.jpg)






![Fig 8 Soluble CR1 concentration (ng/ml) in plasma from donors with different CR1 SNPs and diagnosis. Soluble CR1 was measured by ELISA and plotted vs. A. SNP [rs6656401 only (n = 21) or rs6656401 and rs4844609 (n = 16) and without the rs6656401 and rs4844609 SNPs (n = 22)] or B. categorized by diagnosis [nondemented (n = 22),), MCI (n = 14) and AD (n = 19)]. Recombinant CR1 was used to generate the standard curve. Black symbols indicate samples with no variant SNP (rs6656401 and rs4844609), red reflects donors with two SNPs, and blue is donors with rs6656401 only. Data points are from multiple experiments in which samples were run in triplicate and normalized to standard CR1 samples across experiments.](https://figures.cochat.ai/paper-figures/536f20347e134662a8bae02798ccb059/analysis-of-the-putative-role-of-cr1-in-alzheimers-disease-genetic-association-figure-8.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CR1 is predominantly expressed by erythrocytes (343, 344) and A 𝛃 -C3b-CR1-mediated interactions sequester A 𝛃 42 to promote clearance to periphery (180, 338), suggesting that CR1 variants can increase free blood A 𝛃 levels (343), which in turn can promote RAGE-mediated A 𝛃 re-entry across the BBB into the brain.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [180]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Our analyses also nominate alternative candidates at three AD risk loci. First, the association at 1q32.2 has been linked to CR153–55, but we observed a colocalized association for both CR1 and CR2 levels with AD risk (Supp. Fig. 23).”
From Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer’s disease (2024) · cites this paper as [53]
In the citing paper
“expression studies in human brain parenchyma found very modest correlations between CR1 expression and AD-associated CR1 genetic variants (142).”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [142]
In the citing paper
“AD-associated genes include CR1 (complement receptor 1), which plays roles in phagocytosis, clearing of immune complexes, and inhibition of complement (Khera and Das, 2009; Fonseca et al., 2016), and CLU/apoJ, which reportedly can function as an inhibitor of the terminal complement complex (Murphy et al., 1989; Tschopp et al., 1993; McDonald and Nelsestuen, 1997).”
From Microglia in Alzheimer’s disease (2018) · cites this paper as Fonseca et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
The Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657
Weisman, H. F., Bartow, T., Leppo, M. K., Marsh, H. C., Carson, G. R., Concino, M. F., Boyle, M. P., Roux, K. H., Weisfeldt, M. L., & Fearon, D. T. (1990) · Science · doi:10.1126/science.2371562 · Cited by 977
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · cited 1×
“Detrimental and neuroprotective effects of the complement system have been shown in Alzheimer’s disease as well as other neurodegenerative diseases (reviewed in [39,40].”
BackgroundSelf-citationComplement activation by beta-amyloid in Alzheimer disease.
Rogers, J., Cooper, N. R., Webster, S., Schultz, J., McGeer, P. L., Styren, S. D., Civin, W. H., Brachova, L., Bradt, B., & Ward, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10016 · Cited by 817
Self-citationRaff, M., Abney, E., Cohen, J., Lindsay, R., & Noble, M. (1983) · The Journal of Neuroscience · doi:10.1523/jneurosci.03-06-01289.1983 · Cited by 759
Deane, R., Bell, R., Sagare, A., & Zlokovic, B. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601867 · Cited by 548
Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms
Ricklin, D., & Lambris, J. D. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203487 · Cited by 478
Cited by
Microglia Function in the Central Nervous System During Health and Neurodegeneration
Colonna, M., & Butovsky, O. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052358 · Cited by 2,894
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Microglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935
Microglia emerge as central players in brain disease
Salter, M. W., & Stevens, B. (2017) · Nature Medicine · doi:10.1038/nm.4397 · Cited by 1,767
Verkhratsky, A., & Nedergaard, M. (2018) · Physiological Reviews · doi:10.1152/physrev.00042.2016 · Cited by 1,678
Metadata
- Authors
- Fonseca, M. I., Chu, S., Pierce, A. L., Brubaker, W. D., Hauhart, R. E., Mastroeni, D., Clarke, E. V., Rogers, J., Atkinson, J. P., & Tenner, A. J.
- Affiliations
- University of California, Irvine (US)
- SRI International (US)
- Washington University in St. Louis (US)
- Maastricht University Medical Centre (NL)
- Corresponding author
- Tenner, Andrea J.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-02-25
- Volume
- 11
- Issue
- 2
- Pages
- e0149792
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4767815
- OpenAlex
- W2277126095
- Cited by
- 87
- References
- 67
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 7 · 2023: 9 · 2022: 5 · 2021: 10 · 2020: 10 · 2019: 6 · 2018: 15 · 2017: 14 · 2016: 3
- FWCI
- 10.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Northwestern University
- National Institutes of Health (AG00538, AG16573)
- National Institute on Aging (P01AG000538, R01AG039750, P50 AG 16573, AG 16573, AG007367, AG039750, AG 00538, P50AG016573, R01AG007367, R56AG007367)
- National Institute of Allergy and Infectious Diseases (R01AI041592)
- National Institute of Neurological Disorders and Stroke (R01NS035144, NS35144)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR048335)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- complement receptor 1, Alzheimer's disease, late-onset Alzheimer's disease, single nucleotide polymorphisms, C1q binding, C3b binding, astrocytes, soluble CR1, complement system, neuroinflammation, genetic association
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Astrocytes, Brain, Complement C3b, Erythrocytes, Female, Gene Expression Regulation, Humans, Male, Complement C1q, Receptors, Complement 3b, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Protein Transport
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Analysis of the Putative Role of CR1 in Alzheimer’s Disease: Genetic Association, Expression and Function. https://app.cochat.ai/papers/10.1371/journal.pone.0149792
- The paper
- Fonseca, M. I., Chu, S., Pierce, A. L., Brubaker, W. D., Hauhart, R. E., Mastroeni, D., Clarke, E. V., Rogers, J., Atkinson, J. P., & Tenner, A. J. (2016). Analysis of the Putative Role of CR1 in Alzheimer’s Disease: Genetic Association, Expression and Function. PLOS ONE. https://doi.org/10.1371/journal.pone.0149792
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.